1
|
Liu W, Li Y, Wang Q, Su H, Ding K, Shuang Y, Gao S, Zou D, Jing H, Chai Y, Zhang Y, Liu L, Wang C, Liu H, Lin J, Zhu H, Yao C, Yan X, Shang M, Wang S, Chang F, Wang X, Zhu J, Song Y. YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial. Front Med (Lausanne) 2021; 8:609116. [PMID: 33604348 PMCID: PMC7884449 DOI: 10.3389/fmed.2021.609116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 01/04/2021] [Indexed: 12/14/2022] Open
Abstract
Background: YF-H-2015005, a novel CXCR4 antagonist, has been proven to increase the quantities of circulating hematopoietic stem cells (HSCs), which results in an adequate collection of HSCs in non-Hodgkin lymphoma (NHL) patients. Methods: This was a multicenter, double-blind, randomized (1:1), placebo-controlled phase III clinical trial. All patients received granulocyte colony-stimulating factor (G-CSF) for up to 8 consecutive days. YF-H-2015005 or placebo was administrated on the evening of day 4 and continued daily for up to 4 days. Apheresis was conducted 9–10 h after each dose of YF-H-2015005 or placebo. The primary endpoint was the proportion of NHL patients procuring ≥5 × 106/kg CD34+ HSCs within ≤4 apheresis sessions. Results: In total, 101 patients with NHL were enrolled. The proportions of patients achieving primary endpoint were 57 and 12% in YF-H-2015005 and placebo groups, respectively (P < 0.001). Moreover, a higher proportion of YF-H-2015005-treated patients reached a minimum target collection of ≥2 × 106/kg CD34+ HSCs in ≤4 apheresis days compared to placebo-treated patients (86 vs. 38%, P < 0.001). Furthermore, the median time to collect ≥2 or 5 × 106/kg CD34+ HSCs were 1 and 3 days in YF-H-2015005-treated patients, but 4 days and not reached in placebo-treated patients, respectively. No severe treatment emergent adverse events were observed in both YF-H-2015005 treatment and placebo groups. Conclusions: YF-H-2015005 plus G-CSF regimen was a tolerable combination with high efficacy, which might be used to rapidly mobilize and collect HSCs in NHL patients.
Collapse
Affiliation(s)
- Weiping Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - Yufu Li
- Department of Hematology, Henan Cancer Hospital, Zhengzhou, China
| | - Quanshun Wang
- Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Hang Su
- Department of Lymphoma, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Kaiyang Ding
- Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
| | - Yuerong Shuang
- Department of Lymphoma & Hematology, Jiangxi Cancer Hospital, Nanchang, China
| | - Sujun Gao
- Department of Hematology, First Affiliated Hospital of Jilin University, Changchun, China
| | - Dehui Zou
- Department of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
| | - Hongmei Jing
- Department of Hematology, Peking University Third Hospital, Beijing, China
| | - Ye Chai
- Department of Hematology, Lanzhou University Second Hospital, Lanzhou, China
| | - Yicheng Zhang
- Department of Hematology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Lihong Liu
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Chunling Wang
- Department of Hematology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China
| | - Hui Liu
- Department of Hematology, Beijing Hospital, Beijing, China
| | - Jinying Lin
- Department of Hematology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
| | - Haiyan Zhu
- Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Chen Yao
- Department of Medical Statistics, Peking University First Hospital, Beijing, China
| | - Xiaoyan Yan
- Peking University Clinical Research Institute, Beijing, China
| | - Meixia Shang
- Department of Medical Statistics, Peking University First Hospital, Beijing, China
| | - Shufang Wang
- Hefei Yifan Biopharmaceuticals Inc., Economic Development Zone, Hefei, China
| | - Fengyuan Chang
- Hefei Yifan Biopharmaceuticals Inc., Economic Development Zone, Hefei, China
| | - Xiaopei Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - Jun Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - Yuqin Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| |
Collapse
|